5 Biotechs Awaiting FDA Decisions in January 2018 Post author:Sam Post published:December 27, 2017 Post category:BioPharma From 1997 through 2013, there was an average of 27 novel drugs approved in the U.S. per year. Source: BioSpace You Might Also Like On a Roll: FDA OKs Genentech's Gazyva for Untreated Follicular Lymphoma November 16, 2017 Pfizer Quietly Takes Passive Stake in This Boston Pharma October 18, 2017 Catabasis To Present Results From The Open-Label Extension Of The Movedmd Phase II Trial Of Edasalonexent In Duchenne Muscular Dystrophy In A Late Breaking Session Of The World Muscle Society September 14, 2017
Catabasis To Present Results From The Open-Label Extension Of The Movedmd Phase II Trial Of Edasalonexent In Duchenne Muscular Dystrophy In A Late Breaking Session Of The World Muscle Society September 14, 2017